First-Line Therapy of Mutated Non-Small Cell Lung Cancer: An Update

Publisher： Karger

E-ISSN： 2296-5262|35|5|293-299

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.5, 2012-04, pp. : 293-299

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel as a Single Agent in First-Line Therapy of Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2004-11 ,pp. : 16-17

Karger

Access to resources Recommend Favorite

Inflammation‐Related Genetic Variations and Survival in Patients With Advanced Non–Small Cell Lung Cancer Receiving First‐Line Chemotherapy

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 360-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system

By Le Lay K.   Myon E.   Hill S.   Riou-Franca L.   Scott D.   Sidhu M.   Dunlop D.   Launois R.  

The European Journal of Health Economics, Vol. 8, Iss. 2, 2007-06 ,pp. : 145-151

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 382-390

Karger

Access to resources Recommend Favorite

Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 350-355

Karger

Access to resources Recommend Favorite